Metropolis Healthcare Unveils TruHealth Cancer Screen 360 for Early Cancer Detection
The test includes gender-specific diagnostics and hereditary risk assessments, aiming to expand access to cancer screening in both urban and non-urban regions.
Metropolis Healthcare has introduced the TruHealth Cancer Screen 360, a comprehensive cancer screening panel designed to improve early cancer detection and preventive oncology in India.
The test includes gender-specific diagnostics and hereditary risk assessments, aiming to expand access to cancer screening in both urban and non-urban regions.
The TruHealth Cancer Screen 360 features scientifically curated Male and Female Profiles to provide early diagnostic insights for commonly occurring cancers, including breast, cervical, ovarian, liver, lung, prostate, colorectal, and thyroid cancers. The panel includes tumor marker testing, hereditary cancer risk analysis covering over 25 cancer types, and organ-specific assessments.
It also incorporates prostate-specific antigen (PSA) testing for men and HPV self-sampling kits for cervical cancer screening in women, as recommended by the World Health Organization.
Surendran Chemmenkottil, CEO of Metropolis Healthcare, said, "The introduction of TruHealth Cancer Screen 360 Male and Female Profiles reflects our unwavering commitment to strengthening preventive healthcare in India. By equipping individuals with timely and reliable diagnostic tools, we aim to empower them to take charge of their health. Early detection is key to reducing the burden of late-stage cancer, improving outcomes, and saving lives."
Addressing India's Cancer Screening Gap
According to the Global Cancer Observatory (GLOBOCAN) 2022 data, India ranks third in cancer incidence and second in cancer-related mortality in South-East Asia.
Screening coverage for common cancers like cervical, breast, and oral cancers remains below 1 percent. This is significantly lower than the World Health Organization's target of 70 percent screening coverage for cervical cancer.
Dr. Kirti Chadha, Senior Oncopathologist and Chief Scientific and Innovation Officer at Metropolis Healthcare, emphasized the urgency of integrating targeted cancer screening into routine health check-ups.
"The TruHealth Cancer Screen 360 has been developed as an evidence-based, comprehensive tool beyond general wellness testing. By incorporating a broad spectrum of biomarkers and hereditary risk indicators, it facilitates early identification of cancer risks—even before symptoms appear," Dr. Chadha said.
The screening also includes a NextGen genetic panel analyzing 317 genes for hereditary cancer risk. It provides free genetic counseling to help individuals understand their results and plan appropriate follow-up care.
Furthermore, Metropolis Healthcare is offering the TruHealth Cancer Screen 360 at an introductory price lower than individual tests, aiming to make advanced cancer diagnostics more accessible and affordable.
Stay tuned for more such updates on Digital Health News
